Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …

Safety data were pooled and analyzed from one phase 2 and two phase 3 double-blind,
placebo-controlled, repeat-dose systemic lupus erythematosus (SLE) trials of belimumab 1 …

Objectives B cells play an important role in the initiation and progression of systemic lupus
erythematosus (SLE). Accordingly, B cell-targeted therapy has been suggested as a new …

Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits
the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent …

Introduction Few treatment options exist for patients with systemic lupus erythematosus
(SLE) who fail conventional therapy. Although widely used to treat lupus, the efficacy of B …

B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus
erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare …

Background: B-cell depletion with rituximab is commonly used for patients with systemic
lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable …

Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …

Introduction Belimumab is a recombinant human monoclonal antibody that binds to soluble
B-lymphocyte stimulator and inhibits its biological activity. Since receiving approvals for the …

Background Belimumab, the first biologic approved for the treatment of systemic lupus
erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE …